Zacks Research Issues Pessimistic Outlook for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research cut their FY2027 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Thursday, July 10th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of $0.06 per share for the year, down from their previous estimate of $0.09. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

Several other analysts also recently weighed in on the stock. Needham & Company LLC reduced their price objective on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, June 17th. Finally, The Goldman Sachs Group dropped their price objective on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $7.00.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR traded down $0.05 during trading on Friday, hitting $1.19. 2,092,368 shares of the company were exchanged, compared to its average volume of 4,759,001. The stock has a market capitalization of $235.86 million, a P/E ratio of -1.49 and a beta of 0.70. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $3.94. The firm's 50 day moving average price is $1.01 and its 200-day moving average price is $1.43.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%. The business had revenue of $65.00 million during the quarter, compared to analysts' expectations of $54.97 million.

Institutional Trading of Esperion Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ESPR. Sivia Capital Partners LLC purchased a new stake in Esperion Therapeutics during the 2nd quarter valued at approximately $25,000. Meridian Wealth Management LLC purchased a new position in Esperion Therapeutics in the 1st quarter valued at $29,000. Cibc World Markets Corp purchased a new position in Esperion Therapeutics in the 4th quarter valued at $39,000. Synergy Asset Management LLC grew its position in Esperion Therapeutics by 3,496.3% in the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 30,138 shares during the last quarter. Finally, Private Advisor Group LLC grew its position in Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock valued at $58,000 after buying an additional 10,000 shares during the last quarter. 47.39% of the stock is owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.